Stem Cell Patents Come Under Fire
By Associated Press,
Associated Press
| 07. 19. 2006
MILWAUKEE -- A consumer group, a patent foundation and a stem cell scientist are challenging patents on human embryonic stem cells held by the Wisconsin Alumni Research Foundation.
The Public Patent Foundation, the Foundation for Taxpayer and Consumer Rights, and Jeanne Loring, a stem cell scientist at the Burnham Institute for Medical Research in California, claim that the patents hinder research, push scientists to pursue work overseas and represent a waste of taxpayer money.
"It's absolutely absurd that one person or organization could own the rights to life itself," said John Simpson, stem cell project director of the Foundation for Taxpayer and Consumer Rights, based in California.
The Wisconsin Alumni Research Foundation _ or WARF _ is the patenting and licensing arm of the University of Wisconsin. University researcher Jamie Thomson first isolated embryonic stem cells in 1998.
WARF director Carl Gulbrandsen said he was confident the patents are valid, saying the challenge was motivated by politics and money.
"WARF stem cell patents do not inhibit research," he said. "They support and encourage it."
Simpson, Loring and others announced their...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
